{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Sana Biotechnology Inc. Life Sciences Inc., (\"Sana\"), located in Seattle, Washington.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/09/13/2021-19618.html","cfr_references":[],"citation":"86 FR 50895","comment_url":null,"comments_close_on":"2021-09-28","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before September 28, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-19618","effective_on":null,"end_page":50897,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/09/13/2021-19618.xml","html_url":"https://www.federalregister.gov/documents/2021/09/13/2021-19618/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-allogeneic-t","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-19618?publication_date=2021-09-13","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-09-13/2021-19618/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":435,"last_updated":"2026-04-04 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-09-13/pdf/2021-19618.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-19618.pdf?1631277924","publication_date":"2021-09-13","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/09/13/2021-19618.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:46:25Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":50895,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Allogeneic T Cell and Gene Therapy Vector Chimeric Antigen Receptor (CAR) Therapies Targeting CD22 Alone or in Combination With CARs Targeting CD19 for the Treatment of B-Cell Malignancies","toc_doc":"Development and Commercialization of Allogeneic T Cell and Gene Therapy Vector Chimeric Antigen Receptor Therapies Targeting CD22 Alone or in Combination with CARs Targeting CD19 for the Treatment of B-Cell Malignancies","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}